Leukemia, Chronic Myeloid disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

CML MCID: LKM063 MIFTS: 74	Leukemia, Chronic Myeloid (CML) Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Leukemia, Chronic Myeloid

MalaCards integrated aliases for Leukemia, Chronic Myeloid:

Name: Leukemia, Chronic Myeloid ⁵⁷ ⁵³ ⁷⁵ ¹³ ³⁸

Chronic Myelogenous Leukemia ¹² ⁷⁶ ⁵³ ²⁵ ⁵⁹ ⁷⁵ ²⁹ ⁶ ¹⁵

Chronic Myeloid Leukemia ³⁸ ¹² ⁵³ ²⁵ ⁵⁹ ³⁷ ⁴³ ¹⁵

Cml ⁵⁷ ¹² ⁵³ ²⁵ ⁵⁹ ⁷⁵

Chronic Granulocytic Leukemia ¹² ⁵³ ²⁵ ⁵⁹

Leukemia, Chronic Myeloid, Atypical ⁷⁵ ²⁹

Myeloid Leukemia, Chronic ¹² ⁷³

Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative ⁷³

Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative ⁷⁵

Leukemia, Myelogenous, Chronic, Bcr-Abl Positive ⁴⁴

Leukemia, Chronic Myeloid, Somatic ⁵⁷

Cml - Chronic Myelogenous Leukemia ¹²

Leukemia, Chronic Myelogenous ⁵⁷

Chronic Myelocytic Leukemia ²⁵

Leukemia, Myeloid, Chronic ⁴⁰

Myeloid Leukemia Chronic ⁵⁵

Acml ⁷⁵

Cgl ²⁵

Characteristics:

Orphanet epidemiological data:

⁵⁹

chronic myeloid leukemia
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (United States); Age of onset: Adult;

OMIM:

⁵⁷

Inheritance:
somatic mutation

HPO:

³²

leukemia, chronic myeloid:
Inheritance somatic mutation

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Myeloid leukaemia

Chronic myeloid leukaemia [CML], BCR/ABL-positive

Orphanet: ⁵⁹

Rare haematological diseases

External Ids:

OMIM ⁵⁷ 608232

Disease Ontology ¹² DOID:8552

ICD9CM ³⁵ 205.1

MeSH ⁴⁴ D015464

NCIt ⁵⁰ C3174

SNOMED-CT ⁶⁸ 63364005 92818009

Orphanet ⁵⁹ ORPHA521

UMLS via Orphanet ⁷⁴ C0023473

ICD10 via Orphanet ³⁴ C92.1

MedGen ⁴² C0023473 C0349640

KEGG ³⁷ H00004

SNOMED-CT via HPO ⁶⁹ 124975008 16294009 302215000 more

UMLS ⁷³ C0023473 C1292772

Sources

Summaries for Leukemia, Chronic Myeloid

NIH Rare Diseases : ⁵³ The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 521Disease definitionChronic myeloid leukaemia (CML) is the most common myeloproliferative disorder accounting for 15-20% of all leukaemia cases.EpidemiologyIts annual incidence has been estimated at between 1 and 1.5 cases per 100,000 and its prevalence at around 1 in 17,000.Clinical descriptionThe disease is typically triphasic with a chronic phase (CML-CP), accelerated phase (CML-AP) and blast phase (CML-BP). The majority of patients are diagnosed in the chronic phase and may be either asymptomatic (diagnosed through a routine white blood cell count) or present with fatigue, anaemia, weight loss, night sweats or splenomegaly.EtiologyCML is characterised by the presence of the Philadelphia chromosome, an abnormality resulting from a balanced translocation between chromosomes 9 and 22 (t(9;22)(q34;q11.2)). This translocation generates a BCR/ABL gene fusion encoding a constitutively active tyrosine kinase. CML does not appear to be an inherited disease and the factors leading to predisposition for the disorder remain largely unknown.Management and treatmentAlthough an allogeneic bone marrow transplant is viewed as the only curative treatment option, the prognosis for patients improved dramatically with the targeted development of imatinib mesylate. Imatinib mesylate is a competitive inhibitor of BCR/ABL tyrosine kinase activity and has held EU marketing authorisation as an Orphan drug for the treatment of CML since 2001.Visit the Orphanet disease page for more resources.

MalaCards based summary : Leukemia, Chronic Myeloid, also known as chronic myelogenous leukemia, is related to atypical chronic myeloid leukemia and philadelphia-negative chronic myeloid leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Chronic Myeloid is BCR (BCR, RhoGEF And GTPase Activating Protein), and among its related pathways/superpathways are Chronic myeloid leukemia and Endometrial cancer. The drugs Bosulif and Busulfex have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are splenomegaly and fever

Disease Ontology : ¹² A myeloid leukemia that is characterized by over production of white blood cells.

Genetics Home Reference : ²⁵ Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow produces red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In chronic myeloid leukemia, the bone marrow produces too many white blood cells. Initially, these cells function relatively normally. However, as the condition progresses, immature white blood cells called myeloblasts (or blasts) accumulate in the blood and bone marrow. The overgrowth of myeloblasts impairs development of other blood cells, leading to a shortage of red blood cells (anemia) and platelets.

MedlinePlus : ⁴³ Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic myeloid leukemia (CML), there are too many granulocytes, a type of white blood cell. Most people with CML have a gene mutation (change) called the Philadelphia chromosome. Sometimes CML does not cause any symptoms. If you have symptoms, they may include: Fatigue Weight loss Night sweats Fever Pain or a feeling of fullness below the ribs on the left side Tests that examine the blood and bone marrow diagnose CML. Treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : ⁷⁵ Leukemia, chronic myeloid: A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts. Leukemia, chronic myeloid, atypical: A myeloproliferative disorder that shares clinical and laboratory features with chronic myeloid leukemia but lacks the pathognomonic Philadelphia chromosome and the corresponding BCR/ABL1 fusion transcript. Features include myeloid predominance in the bone marrow, myeloid proliferation and low leukocyte alkaline phosphatase value, splenomegaly, hepatomegaly, elevated white blood cell count. Enlarged spleen may also be associated with a hypermetabolic state, fever, weight loss, and chronic fatigue. The enlarged liver may contribute to the patient's weight loss.

Wikipedia : ⁷⁶ Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a cancer of the white... more...

Description from OMIM: 608232

Sources

Related Diseases for Leukemia, Chronic Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid	Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia	Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Chronic Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 415)

#	Related Disease	Score	Top Affiliating Genes
1	atypical chronic myeloid leukemia	34.7	ABL1 CSF3R JAK2 PDGFRA RUNX1 SETBP1
2	philadelphia-negative chronic myeloid leukemia	34.2	ABL1 BCR
3	leukemia	33.0	ABL1 BCR CSF3R HOTAIR JAK2 NRAS
4	juvenile myelomonocytic leukemia	32.9	JAK2 NRAS PDGFRA RUNX1 SETBP1
5	myelodysplastic myeloproliferative cancer	32.5	ABL1 CSF3R JAK2 NRAS SETBP1
6	myeloid leukemia	31.5	ABL1 BCR CSF3R JAK2 NRAS RUNX1
7	leukemia, acute lymphoblastic	31.2	ABL1 BCR MIR203A MIR223 RUNX1
8	chronic leukemia	31.0	BCR CSF3R JAK2 SETBP1
9	essential thrombocythemia	31.0	ABL1 BCR JAK2 MIR223
10	chronic myelomonocytic leukemia	30.9	CSF3R JAK2 RUNX1 SETBP1
11	leukemia, acute myeloid	30.9	ABL1 BCR CSF3R HOTAIR JAK2 MEG3
12	polycythemia vera	30.8	ABL1 H19 JAK2 PDGFRA
13	myeloma, multiple	30.8	H19 HOTAIR JAK2 MEG3 NRAS UCA1
14	myeloproliferative neoplasm	30.5	ABL1 BCR H19 JAK2 PDGFRA
15	colorectal cancer	30.3	H19 HOTAIR HULC MEG3 MIR10A MIR203A
16	myelodysplastic syndrome	30.3	ABL1 CSF3R JAK2 MEG3 MIR10A NRAS
17	glioblastoma	30.3	H19 HOTAIR MEG3 NRAS PDGFRA
18	thyroid cancer, nonmedullary, 1	30.3	H19 HOTAIR HULC MEG3
19	melanoma	30.3	H19 HOTAIR MEG3 NRAS UCA1
20	diffuse large b-cell lymphoma	30.2	HOTAIR HULC MIR10A
21	bladder cancer	30.2	H19 HOTAIR HULC MEG3 MIR10A MIR203A
22	nasopharyngeal carcinoma	30.2	H19 HOTAIR HULC MEG3 NRAS
23	medulloblastoma	30.2	H19 HOTAIR MIR20A NRAS PDGFRA
24	acute promyelocytic leukemia	30.1	CSF3R MIR223 NRAS RUNX1
25	pdgfrb-associated chronic eosinophilic leukemia	11.8
26	myelocytic leukemia-like syndrome, familial, chronic	11.2
27	lipodystrophy, congenital generalized, type 2	11.1
28	lipodystrophy, congenital generalized, type 1	11.1
29	hematopoietic stem cell transplantation	10.5
30	chromosome 22q11.2 deletion syndrome, distal	10.4	BCR CRKL
31	sarcoma	10.4
32	leukemia, acute lymphoblastic 3	10.4	ABL1 BCR PDGFRA RUNX1
33	ovarian epithelial cancer	10.4	H19 HOTAIR HULC MEG3
34	neutrophilia, hereditary	10.4	CSF3R JAK2 MIR223
35	pituitary adenoma	10.4	H19 HOTAIR MEG3 MIR223
36	gastric cardia adenocarcinoma	10.4	H19 HOTAIR MEG3
37	bone marrow cancer	10.4	ABL1 BCR CSF3R IRF8 JAK2 PDGFRA
38	functionless pituitary adenoma	10.4	HOTAIR MEG3
39	pancreatic ductal adenocarcinoma	10.4	H19 HOTAIR MIR203A MIR223 UCA1
40	core binding factor acute myeloid leukemia	10.4	JAK2 NRAS RUNX1
41	hematologic cancer	10.4	ABL1 BCR CSF3R JAK2 RUNX1
42	osteogenic sarcoma	10.4	H19 HOTAIR HULC MEG3 UCA1
43	oral squamous cell carcinoma	10.4	H19 HOTAIR MEG3 MIR10A MIR203A MIR223
44	kidney cancer	10.4	H19 HOTAIR MEG3 MIR20A
45	glioma	10.4	H19 HOTAIR HULC MEG3 MIR20A PDGFRA
46	adamantinoma of long bones	10.4	H19 HOTAIR HULC MEG3 UCA1
47	myeloid sarcoma	10.4
48	gallbladder cancer	10.4	H19 HOTAIR MEG3 UCA1
49	esophageal cancer	10.4	H19 HOTAIR HULC MEG3 MIR203A MIR223
50	lymphoma	10.4

Comorbidity relations with Leukemia, Chronic Myeloid via Phenotypic Disease Network (PDN):

Acute Cystitis	Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Leukemia, Chronic Myeloid:

Sources

Symptoms & Phenotypes for Leukemia, Chronic Myeloid

Symptoms via clinical synopsis from OMIM:

⁵⁷

Hematology:
chronic myelogenous leukemia
ph-positive acute lymphoblastic leukemia

Laboratory Abnormalities:
low leukocyte alkaline phosphatase activity
presence of the philadelphia chromosome (translocation of 9q34 and 22q11) in greater than 95% of patients
two alternative chimeric oncogene products called p210(bcr-abl) and p185(bcr-abl)
detection by rt-pcr, southern blot analysis, and fish for primary diagnosis and follow up for residual disease

Clinical features from OMIM:

608232

Human phenotypes related to Leukemia, Chronic Myeloid:

⁵⁹ ³² (show all 15)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	splenomegaly ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001744
2	fever ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001945
3	fatigue ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0012378
4	thrombocytopenia ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001873
5	thrombocytosis ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001894
6	leukocytosis ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001974
7	poor appetite ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0004396
8	myeloproliferative disorder ⁵⁹ ³²	obligate (100%)	Obligate (100%)	HP:0005547
9	abnormality of blood and blood-forming tissues ⁵⁹		Frequent (79-30%)
10	abnormality of granulocytes ⁵⁹		Frequent (79-30%)
11	abnormality of basophils ⁵⁹		Frequent (79-30%)
12	chronic myelogenous leukemia ³²			HP:0005506
13	ph-positive acute lymphoblastic leukemia ³²			HP:0004848
14	reduced leukocyte alkaline phosphatase ³²			HP:0004852
15	abnormal basophil morphology ³²	frequent (33%)		HP:0001912

UMLS symptoms related to Leukemia, Chronic Myeloid:

angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Leukemia, Chronic Myeloid:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	liver/biliary system	MP:0005370	9.5	ABL1 BCR CRKL IRF8 JAK2 NRAS
2	neoplasm	MP:0002006	9.1	CRKL IRF8 JAK2 NRAS PDGFRA RUNX1

Sources

Drugs & Therapeutics for Leukemia, Chronic Myeloid

FDA approved drugs:

(show all 7)

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Bosulif ¹⁸ ⁴⁹	BOSUTINIB MONOHYDRATE	Pfizer	September 2012
FDA Label: Bosulif Disease/s that Drug Treats:Ph+ chronic myelogenous leukemia Indications and Usage: ¹⁸ BOSULIF is a kinase inhibitor indicated for the treatment of adult patientswith chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia(CML) with resistance or intolerance to prior therapy. (1) DrugBank Targets: ¹⁶ 1. Breakpoint cluster region protein;2. Tyrosine-protein kinase ABL1;3. Tyrosine-protein kinase Lyn;4. Tyrosine-protein kinase HCK;5. Proto-oncogene tyrosine-protein kinase Src;6. Cyclin-dependent kinase 2;7. Dual specificity mitogen-activated protein kinase kinase 1;8. Dual specificity mitogen-activated protein kinase kinase 2;9. Mitogen-activated protein kinase kinase kinase 2;10. Calcium/calmodulin-dependent protein kinase type II subunit gamma Mechanism of Action: ¹⁸ Target: tyrosine kinase/ Src-family kinases including Src, Lyn, and Hck Action: inhibitor FDA: Bosutinib is a tyrosine kinase inhibitor. Bosutinib inhibits the Bcr-Abl kinase that promotes CML; it is also aninhibitor of Src-family kinases including Src, Lyn, and Hck. Bosutinib inhibited 16 of 18 imatinib-resistant forms ofBcr-Abl expressed in murine myeloid cell lines. Bosutinib did not inhibit the T315I and V299L mutant cells. In mice,treatment with bosutinib reduced the size of CML tumors relative to controls and inhibited growth of murine myeloidtumors expressing several imatinib-resistant forms of Bcr-Abl.
2	Busulfex ¹⁸ ⁴⁹	BUSULFAN	Orphan Medical	February 1999
FDA Label: Busulfex Disease/s that Drug Treats:leukemia Indications and Usage: ¹⁸ BUSULFEX is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimenprior to allogeneic hematopoietic progenitor cell transplantation forchronic myelogenous leukemia (CML) (1) DrugBank Targets: ¹⁶ DNA Mechanism of Action: ¹⁸ Target: DNA Action: alkylyzer FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of afour-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This producesreactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity ofbusulfan.
3	Gleevec ¹⁸ ⁴⁹	IMATINIB MESYLATE	Novartis	May 2001
FDA Label: Gleevec Disease/s that Drug Treats:chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs) Indications and Usage: ¹⁸ Gleevecâ¢ (imatinib mesylate) is indicated for the treatment of newly diagnosed adultpatients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronicphase. Follow-up is limited. Page 10Gleevec is also indicated for the treatment of patients with Philadelphia chromosomepositive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronicphase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment ofpediatric patients with Ph+ chronic phase CML whose disease has recurred after stem celltransplant or who are resistant to interferon alpha therapy. There are no controlled trialsdemonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.Gleevec is also indicated for the treatment of patients with Kit (CD117) positiveunresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (SeeCLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec inGIST is based on objective response rate (see CLINICAL STUDIES). There are no controlledtrials demonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival. DrugBank Targets: ¹⁶ 1. BCR/ABL fusion protein isoform X9;2. Mast/stem cell growth factor receptor Kit;3. RET proto-oncogene;4. High affinity nerve growth factor receptor;5. Macrophage colony-stimulating factor 1 receptor;6. Platelet-derived growth factor receptor alpha;7. Epithelial discoidin domain-containing receptor 1;8. Tyrosine-protein kinase ABL1;9. Platelet-derived growth factor receptor beta Mechanism of Action: ¹⁸ Target: protein-tyrosine kinase Action: inhibitor FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosinekinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosomeabnormality in chronic myeloid leukemia (CML). It inhibits proliferation and inducesapoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphiachromosome positive chronic myeloid leukemia. In colony formation assays using ex vivoperipheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positivecolonies from CML patients.In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as wellas Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derivedgrowth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- andSCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis ingastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
4	Iclusig ¹⁸ ⁴⁹	PONATINIB HYDROCHLORIDE	Ariad Pharmaceuticals	December 2012
FDA Label: Iclusig Disease/s that Drug Treats:chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia Indications and Usage: ¹⁸ Iclusig is a kinase inhibitor indicated for the: Treatment of adult patients with T315I-positive chronic myeloidleukemia (chronic phase, accelerated phase, or blast phase) or T315IpositivePhiladelphia chromosome positive acute lymphoblasticleukemia (Ph+ ALL). Treatment of adult patients with chronic phase, accelerated phase, orblast phase chronic myeloid leukemia or Ph+ ALL for whom no othertyrosine kinase inhibitor (TKI) therapy is indicated. (1)These indications are based upon response rate. There are no trials verifying animprovement in disease-related symptoms or increased survival with Iclusig. DrugBank Targets: ¹⁶ 1. Tyrosine-protein kinase ABL1;2. Breakpoint cluster region protein;3. Mast/stem cell growth factor receptor Kit;4. Proto-oncogene tyrosine-protein kinase receptor Ret;5. Angiopoietin-1 receptor;6. Receptor-type tyrosine-protein kinase FLT3;7. Fibroblast growth factor receptor 1;8. Fibroblast growth factor receptor 2;9. Fibroblast growth factor receptor 3;10. Fibroblast growth factor receptor 4;11. Tyrosine-protein kinase Lck;12. Proto-oncogene tyrosine-protein kinase Src;13. Tyrosine-protein kinase Lyn;14. Vascular endothelial growth factor receptor 2;15. Platelet-derived growth factor receptor alpha Mechanism of Action: ¹⁸ Target: tyrosine kinase activity of ABL and T315I mutant ABL Action: inhibitor FDA: Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL withIC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRCfamilies of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native ormutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native orT315I mutant BCR-ABL when compared to controls.
5	Sprycel ¹⁸ ⁴⁹	DASATINIB	Bristol-Myers Squibb	June 2006
FDA Label: Sprycel Disease/s that Drug Treats:Chronic Myeloid Leukemia Indications and Usage: ¹⁸ SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+)chronic myeloid leukemia (CML) in chronic phase. (1, 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib. (1,14) adults with Philadelphia chromosome-positive acute lymphoblasticleukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14) DrugBank Targets: ¹⁶ 1. Tyrosine-protein kinase ABL1;2. Proto-oncogene tyrosine-protein kinase Src;3. Ephrin type-A receptor 2;4. Tyrosine-protein kinase Lck;5. Tyrosine-protein kinase Yes;6. Mast/stem cell growth factor receptor Kit;7. Platelet-derived growth factor receptor beta;8. Signal transducer and activator of transcription 5B;9. Abelson tyrosine-protein kinase 2;10. Tyrosine-protein kinase Fyn Mechanism of Action: ¹⁸ Target: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRÎ² kinases Action: inhibitor FDA: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRÎ². Based on modeling studies, dasatinib ispredicted to bind to multiple conformations of the ABL kinase.In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylatesensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia(CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under theconditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABLkinase domain mutations, activation of alternate signaling pathways involving the SRCfamily kinases (LYN, HCK), and multi-drug resistance gene overexpression.
6	Synribo ¹⁸ ⁴⁹	OMACETAXINE MEPESUCCINATE	Teva Pharmaceutical	October 2012
FDA Label: Synribo Disease/s that Drug Treats:chronic or accelerated phase chronic myeloid leukemia Indications and Usage: ¹⁸ SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI) (1) DrugBank Targets: ¹⁶ 1. 50S ribosomal protein L2;2. 60S ribosomal protein L3 Mechanism of Action: ¹⁸ Target: A-site cleft in the peptidyl-transferase center of thelarge ribosomal subunit from a strain of archaeabacteria Action: inhibitor of protein synthesis FDA: The mechanism of action of omacetaxine mepesuccinate has not been fully elucidated but includes inhibition of protein synthesis andis independent of direct Bcr-Abl binding. Omacetaxine mepesuccinate binds to the A-site cleft in the peptidyl-transferase center of thelarge ribosomal subunit from a strain of archaeabacteria. In vitro, omacetaxine mepesuccinate reduced protein levels of the Bcr-Abloncoprotein and Mcl-1, an anti-apoptotic Bcl-2 family member. Omacetaxine mepesuccinate showed activity in mouse models ofwild-type and T315I mutated Bcr-Abl CML.
7	Tasigna ¹⁸ ⁴⁹	NILOTINIB HYDROCHLORIDE MONOHYDRATE	Novartis	October 2007
FDA Label: Tasigna Disease/s that Drug Treats:chronic myelogenous leukemia Indications and Usage: ¹⁸ Tasigna is a kinase inhibitor indicated for:The treatment of newly diagnosed adult patients with Philadelphiachromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML inadult patients resistant to or intolerant to prior therapy that included imatinib.(1.2)-------------- DrugBank Targets: ¹⁶ 1. Tyrosine-protein kinase ABL1;2. Mast/stem cell growth factor receptor Kit Mechanism of Action: ¹⁸ Target: Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF) Action: inhibitor of signal transduction FDA: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation ofthe kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murineleukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of theassays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 outof 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20to 60 nM), PDGFR (69 nM), c-KIT (210 nM), CSF-1R (125 to 250 nM), and DDR1 (3.7 nM).

Drugs for Leukemia, Chronic Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 514)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dasatinib

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

302962-49-8

3062316

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

6055-19-2, 50-18-0

2907

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

135968-09-1

tannic acid

Approved

Phase 4,Phase 2,Phase 3,Phase 1

Benzocaine

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

94-09-7, 1994-09-7

2337

Thiotepa

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

52-24-4

5453

Lactitol

Investigational

Phase 4,Phase 2,Phase 3,Phase 1

585-86-4

3871

Imatinib Mesylate

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

220127-57-1

123596

Protein Kinase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

tyrosine

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antiviral Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interferon-alpha

Phase 4,Phase 3,Phase 2,Phase 1

interferons

Phase 4,Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Alkylating

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antilymphocyte Serum

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Alkylating Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Tin Fluorides

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Hydroxyurea

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

127-07-1

3657

Cytarabine

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

147-94-4

6253

Idarubicin

Approved

Phase 3,Phase 2,Phase 1

58957-92-9

42890

Busulfan

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

55-98-1

2478

Etoposide

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

33419-42-0

36462

Fludarabine

Approved

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1

75607-67-9, 21679-14-1

30751

Iron

Approved

Phase 2, Phase 3,Phase 1,Not Applicable

7439-89-6

23925

Ketamine

Approved, Vet_approved

Phase 3

6740-88-1

3821

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Cefepime

Approved, Investigational

Phase 3,Phase 1

88040-23-7

5479537

Melphalan

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

148-82-3

4053 460612

Decitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

2353-33-5

451668

Azacitidine

Approved, Investigational

Phase 3,Phase 2,Phase 1

320-67-2

9444

leucovorin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

58-05-9

6006 143

Methotrexate

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

59-05-2, 1959-05-2

126941

Miconazole

Approved, Investigational, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Mycophenolic acid

Approved

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1

24280-93-1

446541

Vincristine

Approved, Investigational

Phase 3,Phase 2,Phase 1

57-22-7, 2068-78-2

5978

Mitoxantrone

Approved, Investigational

Phase 3,Phase 2,Phase 1

65271-80-9

4212

Tacrolimus

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

104987-11-3

445643 439492

Vidarabine

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

24356-66-9

32326 21704

Carboplatin

Approved

Phase 2, Phase 3,Phase 1

41575-94-4

10339178 38904 498142

Prednisolone

Approved, Vet_approved

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

50-24-8

5755

Prednisolone phosphate

Approved, Vet_approved

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

302-25-0

Methylprednisolone

Approved, Vet_approved

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

83-43-2

6741

Interventional clinical trials:

(show top 50) (show all 1186)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia	Unknown status	NCT02317159	Phase 4	Imatinib
2	Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib	Unknown status	NCT02389920	Phase 4	Nilotinib
3	Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation	Unknown status	NCT01243489	Phase 4
4	Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission	Unknown status	NCT01901666	Phase 4	Growth Hormone
5	Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response	Completed	NCT01043874	Phase 4	Nilotinib
6	Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia	Completed	NCT00390897	Phase 4	Glivec;Interferon
7	Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial	Completed	NCT01368523	Phase 4	nilotinib
8	Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib	Completed	NCT00644878	Phase 4	Nilotinib
9	Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors	Active, not recruiting	NCT02228382	Phase 4	Bosutinib
10	Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib	Completed	NCT01660906	Phase 4	Dasatinib
11	Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase	Completed	NCT00786812	Phase 4	Nilotinib
12	Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia	Recruiting	NCT03216070	Phase 4	Dasatinib 50 MG
13	An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment	Completed	NCT00980018	Phase 4	Nilotinib
14	Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)	Completed	NCT00171899	Phase 4	imatinib mesylate
15	Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Completed	NCT00081926	Phase 4	Gleevec
16	CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib	Completed	NCT01227577	Phase 4	Nilotinib
17	Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib	Terminated	NCT00461929	Phase 4
18	Efficacy and Safety of Nilotinib in CML-CP	Completed	NCT03332511	Phase 4	Nilotinib
19	A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients	Terminated	NCT02204722	Phase 4	600mg/day of Imatinib;400mg/day of Imatinib
20	Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia	Recruiting	NCT02602314	Phase 4	Imatinib;Nilotinib
21	Glivec in Pediatric Chronic Myeloid Leukemia (CML)	Completed	NCT00845221	Phase 4	Imatinib mesylate 100 mg (Glivec)
22	Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase	Completed	NCT01061177	Phase 4	Nilotinib
23	Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations	Terminated	NCT01131325	Phase 4	nilotinib
24	Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.	Recruiting	NCT02546674	Phase 4	Nilotinib
25	Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients	Active, not recruiting	NCT01578213	Phase 4	Imatinib mesylate
26	Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.	Withdrawn	NCT01605981	Phase 4	AMN107
27	Tasigna in Glivec-resistant or Intolerant Patients in CML	Completed	NCT01206088	Phase 4	nilotinib
28	Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy	Terminated	NCT02086487	Phase 4	Nilotinib 300 mg.
29	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
30	Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia	Unknown status	NCT00002869	Phase 3	cytarabine;hydroxyurea
31	Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia	Unknown status	NCT00002771	Phase 3	busulfan;cytarabine;hydroxyurea;idarubicin
32	Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia	Unknown status	NCT00025402	Phase 3	busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
33	Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase	Unknown status	NCT00327262	Phase 3	Imatinib
34	Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion	Unknown status	NCT00966810	Phase 2, Phase 3
35	Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib	Unknown status	NCT01400074	Phase 3	Nilotinib, Imatinib
36	Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy	Unknown status	NCT00297570	Phase 3	Pegylated Interferon and Imatinib
37	Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain	Unknown status	NCT01316744	Phase 3	ketamine hydrochloride
38	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Unknown status	NCT00020865	Phase 3	cefepime hydrochloride;levofloxacin
39	Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome	Unknown status	NCT00047268	Phase 3	cytarabine;mercaptopurine
40	Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation	Unknown status	NCT01217723	Phase 3
41	Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	Unknown status	NCT00002989	Phase 3	busulfan;cyclophosphamide;idarubicin;melphalan
42	Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome	Unknown status	NCT00043134	Phase 3	decitabine
43	Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality	Not yet recruiting	NCT03746054	Phase 3
44	Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.	Terminated	NCT02108951	Phase 3	Nilotinib
45	Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients	Completed	NCT01254188	Phase 3	Nilotinib
46	Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia	Terminated	NCT03079505	Phase 3	Dasatinib 100 MG [Sprycel];Nilotinib 150mg oral capsule [Tasigna]
47	Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase	Completed	NCT00451035	Phase 2, Phase 3	LBH589
48	Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)	Terminated	NCT01650805	Phase 3	ponatinib;imatinib (Gleevec/ Glivec)
49	A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia	Active, not recruiting	NCT02627677	Phase 3	ponatinib 30 mg QD;ponatinib 15 mg QD;nilotinib 400 mg BID
50	TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study	Active, not recruiting	NCT01657604	Phase 3	Peginterferon α2b;Nilotinib

Search NIH Clinical Center for Leukemia, Chronic Myeloid

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

bosutinib

busulfan

cyclophosphamide

hydroxyurea

idarubicin

idarubicin hydrochloride

interferon alfa-2b

thioguanine

uracil mustard

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Leukemia, Chronic Myeloid cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Leukemia, Chronic Myeloid:

	Hemacord�, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
	Hematopoietic stem cells for treatment of hematologic malignancies
	StemEx�, umbilical cord blood stem/progenitor cells for hematological diseases

Embryonic/Adult Cultured Cells Related to Leukemia, Chronic Myeloid:

	Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD�) PMIDs: 9828244
	Bone marrow-derived hematopoietic stem cells
	Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Cochrane evidence based reviews: leukemia, myelogenous, chronic, bcr-abl positive

Sources

Genetic Tests for Leukemia, Chronic Myeloid

Genetic tests related to Leukemia, Chronic Myeloid:

#	Genetic test	Affiliating Genes
1	Chronic Myelogenous Leukemia ²⁹	BCR
2	Leukemia, Chronic Myeloid, Atypical ²⁹

Sources

Anatomical Context for Leukemia, Chronic Myeloid

MalaCards organs/tissues related to Leukemia, Chronic Myeloid:

⁴¹

Myeloid, Bone, Bone Marrow, T Cells, Spleen, Nk Cells, Neutrophil

Sources

Publications for Leukemia, Chronic Myeloid

Articles related to Leukemia, Chronic Myeloid:

(show top 50) (show all 1600)

#	Title	Authors	Year
1	Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. ( 29941400 )	Won A.M....Chambers M.	2018
2	Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US. ( 29095654 )	Franklin M....Makenbaeva D.	2018
3	A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis. ( 29187020 )	Huho A.N....Punia J.N.	2018
4	Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy. ( 29447062 )		2018
5	Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia. ( 29998167 )	Perdigoto DN...Tom? L	2018
6	Induction of apoptosis and erythroid differentiation of human chronic myelogenous leukemia K562 cells by low concentrations of lidamycin. ( 30542729 )	Zhang C...Chen J	2018
7	Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation. ( 30418193 )	Paul T...Biswas N	2018
8	A modified DAW-22 compound F-B1 inhibits Bcr/Abl and induces apoptosis in chronic myelogenous leukemia cells. ( 30422832 )	Wang F...Mu Y	2018
9	BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance. ( 30455891 )	Mikhailov I	2018
10	Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia. ( 30399426 )	Chandran RK...Sreedharan H	2018
11	Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment. ( 30411262 )	Shah M...Bhatia R	2018
12	LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia. ( 30366670 )	Wen F...Lu ZW	2018
13	Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. ( 30267760 )	Andolina JR...Roth ME	2018
14	Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient. ( 30147933 )	Beaud J...Suner L	2018
15	Acute myeloid leukemia developed in Ph- cells with MLL gene amplification in a patient with chronic myelogenous leukemia. ( 29473433 )	Jiang JG...Wei EX	2018
16	Apoptotic Effects of Some Tetrahydronaphthalene Derivatives on K562 Human Chronic Myelogenous Leukemia Cell Line. ( 28403785 )	Koc A...Karabay AZ	2018
17	Stability Analysis of a Model of Interaction Between the Immune System and Cancer Cells in Chronic Myelogenous Leukemia. ( 28536994 )	Besse A...Lepoutre T	2018
18	PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia. ( 29070525 )	Zhou J...Pan J	2018
19	Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells. ( 29121435 )	Hirao T...Aoki S	2018
20	ITR‑284 modulates cell differentiation in human chronic myelogenous leukemia K562 cells. ( 29138846 )	Yang JS...Tsai SC	2018
21	Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. ( 29179634 )	Ruggiu M...Rousselot P	2018
22	Rhus verniciflua Stokes extract induces inhibition of cell growth and apoptosis in human chronic myelogenous leukemia K562 cells. ( 29328387 )	Lee KW...Kim Y	2018
23	The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities. ( 29386476 )	Ciftci HI...Fujita M	2018
24	Comparative Study of Clinico-hematological Features, Molecular Spectrum and Response to Imatinib in Chronic Myelogenous Leukemia Patients: Pediatric and Adolescent Versus Adults. ( 29398795 )	Tahlan A...Varma S	2018
25	A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion. ( 29406237 )	Alter A...Gildea T	2018
26	TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK/STAT3 signaling pathway in human chronic myelogenous leukemia K562/ADM cells. ( 29436678 )	Ma X...Sun Y	2018
27	Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells. ( 29500416 )	Xu Y...Minato N	2018
28	Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia. ( 29501750 )	Qing X...Mason H	2018
29	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. ( 29505034 )	Zhang B...Marcucci G	2018
30	Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor. ( 29511345 )	Zhu Y...Chen Y	2018
31	Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression. ( 29655913 )	Pan J...Chen L	2018
32	Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib. ( 29719934 )	Kondo T...Inter-Michinoku Dasatinib Study Group (IMIDAS)	2018
33	Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib. ( 29800673 )	Nicolini FE...Etienne G	2018
34	Electrochemical genosensor based on template assisted synthesized polyaniline nanotubes for chronic myelogenous leukemia detection. ( 29853062 )	Soni A...Sumana G	2018
35	Resveratrol inhibits STAT5 activation through the induction of SHP-1 and SHP-2 tyrosine phosphatases in chronic myelogenous leukemia cells. ( 29878900 )	Li Q...Sui T	2018
36	Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia. ( 29901125 )	Zheng Y...Zhang X	2018
37	Chronic myelogenous leukemia on target. ( 29905026 )	N?methov? V...R?zga F	2018
38	A Systems Biology-Based Approach to Uncovering Molecular Mechanisms Underlying Effects of Traditional Chinese Medicine Qingdai in Chronic Myelogenous Leukemia, Involving Integration of Network Pharmacology and Molecular Docking Technology. ( 29934492 )	Zhou C...Sun C	2018
39	Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation. ( 29945329 )	Zeng Y...Liu J	2018
40	Chronic Myelogenous Leukemia Presenting with Facial Nerve Palsy in an Infant. ( 30026776 )	Khajeh A...Keikha R	2018
41	Inhibition of ER stress-related IRE1α/CREB/NLRP1 pathway promotes the apoptosis of human chronic myelogenous leukemia cell. ( 30055408 )	Xu Z...Ji G	2018
42	Prognostic Implications of Derivative Chromosome 9 Deletions in Patients with Advanced-Stage Chronic Myelogenous Leukemia. ( 30055547 )	Chandran RK...Sreedharan H	2018
43	Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation. ( 30078165 )	Chiba A...Kurokawa M	2018
44	Femtosecond laser pulse assisted photoporation for drug delivery in Chronic myelogenous leukemia cells. ( 30098520 )	Banavath HN...Rajasekaran B	2018
45	Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients. ( 30151740 )	Watanabe N...Komatsu N	2018
46	Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia. ( 30181817 )	Guerra B...Fern?ndez-P?rez L	2018
47	Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. ( 30195076 )	Heiblig M...Nicolini FE	2018
48	miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2. ( 30195077 )	Pan B...Ikezoe T	2018
49	A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report. ( 30214807 )	Aria AB...Huen AO	2018
50	Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia. ( 26580245 )	Jabbour E...Lin J	2018

Sources

Genes for Leukemia, Chronic Myeloid

Genes related to Leukemia, Chronic Myeloid (10 elite genes):

(show top 50) (show all 87)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	BCR	BCR, RhoGEF And GTPase Activating Protein	Protein Coding	996.35	Molecular basis known ⁵⁷ Gene fusion ⁵⁹ Genetic Tests ²⁹ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications (show sections)	12011769 2403827 7512367 (more) 2337672 8236869 16616113 1961010 7718887 8818385 1705008 1762103 1639418 8955614 17145570 2157692 1815390 8242587 11374415 11085460 10339507 10200527 10534772 9754444 9349495 8637725 7980523 8237276 8231247 1615925 1372840 1823362 2065022 2395384 18549649 18194660 1932752 2160631 16304380 18313694 18089786 16305488 15166033 12835719 12004080 8597608 7957661 8168080 8321020 19936007 19883308 18095887 17970609 17048290 11672777 10739005 9845542 8127157 1687492 2310695 20040619 19778852 18451307 12820774 11987244 18406870 16546576 15309385 15494376 15248918 12855552 12411298 12439344 17108134 14639002 12970766 12440260 10025763 9525737 8463127 1371078 11587372 11356068 11345196 11196151 10950939 10526530 9544977 8247527 17011977 16281073 16154800 16109618 15757021 15052442 15000831 11739186 8502487 1682032 19850986
2	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	789.54	Pathogenic/Likely pathogenic ⁶ Gene fusion ⁵⁹ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders (show sections)	24976289 18243808 2157692 (more) 16825513 7718887 16616113 19220809 12835719 2198962 18082628 8236869 8175034 8161793 9593259 8242587 10339507 11374415 15000831 2403827 19643477 19168282 16611216 17011977 15503866 12697127 16109618 15757021 12836614 12440260 12181402 11463449 9525737 7694218 8501975 1371078 1932752 15571798 14745431 10739005 2337672 20040619 18406870 15727903 15717993 15309385 16260764 16213359 14645009 12734675 12759927 9426513 8998181 7867215 2267134 19721343 17164333 15946589 15282669 15139047 12869662 12154025 10812245 10498618 8063271 1893079 18391983 16541397 2224129 2407300 20026060 19337199 17504122 17384214 16932346 16778200 12783380 12576428 12527798 1736009 19236722 17155893 15961388 15716362 2160631 20451394 15964830 11345196 11877000 10526530 8647442 8231247 12692682 10988075 7980523 1354683 20048131 10442632 14635208
2	ABL1::MIR203A ⁴⁷	MIR203A Macro RNA (hsa-miR-203) targets ABL1
3	SETBP1	SET Binding Protein 1	Protein Coding	731.17	Pathogenic ⁶ Causative variation ⁷⁵ DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Variants (show sections)	24976289
4	JAK2	Janus Kinase 2	Protein Coding	426.02	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	24976289 9326218 19234487 (more) 18479730 19168282 19951872 16645202 19387008 19860198 16037387 18297515 19427035 18094555 17643100 16818614 17688946
5	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	410.62	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	24976289 9379676 7949098
6	CSF3R	Colony Stimulating Factor 3 Receptor	Protein Coding	409.92	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	24976289 9204982 9548419
7	MIR223	MicroRNA 223	RNA Gene	350	Causal ⁴⁷	17996649
8	MIR10A	MicroRNA 10a	RNA Gene	350	Causal ⁴⁷	19074828
9	MIR20A	MicroRNA 20a	RNA Gene	350	Causal ⁴⁷	17284533
10	MIR203A	MicroRNA 203a	RNA Gene	350	Causal ⁴⁷	18538733
11	BGLT3	Beta Globin Locus Transcript 3	RNA Gene	153.8	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	24837367
12	H19	H19, Imprinted Maternally Expressed Transcript	RNA Gene	152.04	Experimental evidence: Regulation ³⁹ Novoseek inferred ⁵⁵	28776669 24685695 15645136
13	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	RNA Gene	150	Experimental evidence: Expression ³⁹	28069548
14	MEG3	Maternally Expressed 3	RNA Gene	150	Experimental evidence: Regulation ³⁹	14602737
15	UCA1	Urothelial Cancer Associated 1	RNA Gene	150	Experimental evidence: Expression ³⁹	27854515
16	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	150	Experimental evidence: Regulation ³⁹	27875938
17	RUNX1	Runt Related Transcription Factor 1	Protein Coding	49.6	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	8412328 15339695 9209439 (more) 8751483 9234595 18262061 15156182 7675444 8656673 11023523 7780155 8395054 8490181
18	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	30.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15034867 19168282 18369405 (more) 19176456 17403446 19182535 15946589 15995325 19366796 20076959
19	IRF8	Interferon Regulatory Factor 8	Protein Coding	27.59	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	16585609 9414265 16780917 (more) 10430629 18195016 10572090 11823414 19801548 9309144 11369663 14976051
20	CRKL	CRK Like Proto-Oncogene, Adaptor Protein	Protein Coding	27.56	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	7521685 7493940 9593259 (more) 9845531 8083188 12508536 10339478 15864744 8168080 7524758 8978305 10608804 17900686 19966867 10514505
21	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	Protein Coding	26.81	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	12480706 15126530 16143881 (more) 19509233 11840282 11896121 16226710 7690631 10632491 10991971 11914627 18369405 20523867 7536510 9658721 19176456 19236722 1371882 14605878 15332547 15547773 15717993 18718191 12613538 14745431 16596277 17363589 10851076 11790564 15167915 15383930 17403446 19494352 7512174 11740803 15139047 15236194 15946589 17044945 17891251 19182535
22	IL3	Interleukin 3	Protein Coding	25.62	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	10536003 2323674 8220157 (more) 10676644 10865977 9885438 7678084 7544854 8542928 11157490 8440338 7686232 1886426 8769707 9808576 11222392 7923192
23	IFNA1	Interferon Alpha 1	Protein Coding	24.99	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8249110 9362160 11236254 (more) 11865642 1488870 10888114 15850832 12481403 7541766 12857554 1701667 12351404 2350627 2004308 2026184 1520870 1327178 8434957 8475671 8231259 8610733 8652857 8697144 9042664 9241616 9459633 9508169 9593468 9727066 9779702 10572078 10500523 11013272 11446736 11587369 15564735 15870485 16144928 14558948 20065083 2072747 1371081 1553580 7902746 8151139 8647442 8607568 8609708 7643624 7742558 7896213 7514245 8127262 7515733 11719355 11698293 11535501 11877000 10870123 10627443 10607685 9665193 9568727 1370212 1958750 1932740 2109455 17894866 16584610 16633105 15607366 15198956 15010998 14734464 14686704 12970765 12374669 11773172 9552062 9491319 9436922 9193355 8951783 8895687 8769698 8757971 8609718 9180290 9657736 9823946 10553157 10609784 10627442 10985480 11187894 11798827 11369652 11397478 11353767
24	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	24.6	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	12480706 16143881 19509233 (more) 11914627 12181402 19366796 20076959 15547773 15717993 18718191 17363589 14504072 15995325 17403446 15946589
25	CSF2	Colony Stimulating Factor 2	Protein Coding	24.58	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	1740679 8090026 1696165 (more) 15378942 1756324 7544854 9596651 9808576 1704804 9234574 1697646 15328418 1961040 12665687 9885438 8350620 10595817
26	LYN	LYN Proto-Oncogene, Src Family Tyrosine Kinase	Protein Coding	24.45	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	18235045 17432977
27	IFNA2	Interferon Alpha 2	Protein Coding	24.39	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9326220 8271861 2279541 (more) 2350627 2259227 2026184 1520870 7715073 10985480 8127262 11535501 12854039 15377465 10867132 9740087 8251892 1932740 16317737 12784336 11818672 14579725 11960335 8935266 7967060 8251893 15257944 7922012 8296238 8426579 1453769 1913450 10481867 8756097 7639284 1878734 15379127 7896213 8405332 9868341 11872080 8251889 7902746 9009441
28	SLC22A1	Solute Carrier Family 22 Member 1	Protein Coding	24.28	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	18669873 20147974 19954617 (more) 19021069 18559609
29	PRAME	Preferentially Expressed Antigen In Melanoma	Protein Coding	19.15	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17382387 10682862
30	STAT5A	Signal Transducer And Activator Of Transcription 5A	Protein Coding	15.49	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17503465 15820062 8710363 (more) 17431118 7589339 17595328 17900686 16278304
31	CSF3	Colony Stimulating Factor 3	Protein Coding	15.37	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	10975389 9021692 9156241 (more) 10942233 10870123 15378942 10997884 8932840 18988925 12513770 10071133 10536003 15553045 1700239 10028846 1692082 10865977 11187894 8673050 12604417 8691565 7510191 7682859 1691103 16239431 14555323 7544854 1534271 16928319 18305564 12568300 12556557 17064986 15975606 11713374 11222392 11105617 10849533 8881102 8769707 7534141 7511442 1280490 1373689 1696165 19749982 7530135 7511182 7549901 7686232 16428509 16531264 10905769 9370046 11276355 9885438 11161255 18457269 19660724 1698648 7687196
32	CD34	CD34 Molecule	Protein Coding	15.27	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	8672965 10779436 1713638 (more) 7512785 1385276
33	KITLG	KIT Ligand	Protein Coding	14.05	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9746786 16127511 7544854 (more) 12297464 7693028 10830729 10851076 7532038 9596651 7686232 8564703
34	FLT3	Fms Related Tyrosine Kinase 3	Protein Coding	14.02	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	15473940 18925699 8182945 (more) 14976243 17584149 9324277 16938665 17124058 17708788 16321848
35	WT1	Wilms Tumor 1	Protein Coding	13.52	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	12835718 19580340 1317488 (more) 12215010 14704656 11300470 15182334 8321047 12783374 15329907 10733485 12829610 15265366 7949179 8639907 11602325 15538407 8822948 10607714 17688410 16361568 16188642 14560650 12411055 17637262
36	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	13.41	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	11133737 10194451 16611216 (more) 17914733 12543790 17357254 19502192
37	DOK1	Docking Protein 1	Protein Coding	13.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	16823827 9008160
38	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	12.84	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	19394750 15963852 1976871 (more) 10737719 16620554 19309222 7914749 12609962 18524988 16157201 9031075 15958635 12176916 7914748 1972761 10463979 9742631 11523404
39	MCL1	MCL1, BCL2 Family Apoptosis Regulator	Protein Coding	12.66	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17599053 18088462 17595328 (more) 15626746 16007148 17634558
40	NUP98	Nucleoporin 98	Protein Coding	12.66	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	15193442 16651408 11241795 (more) 11681408 11830496
41	ETV6	ETS Variant 6	Protein Coding	12.57	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9326218 9365838 9454771 (more) 19480935
42	CASP3	Caspase 3	Protein Coding	12.56	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	19379562 20030921 12007503
43	CD33	CD33 Molecule	Protein Coding	12.52	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	12375643
44	BCL2L1	BCL2 Like 1	Protein Coding	12.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	15143129 10727459 15972124 (more) 10648417 9475763
45	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	12.37	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	7758616 7493914 17574965 (more) 8317907 9279359 11877000 9743466 12836614 15583844 9154822 10355827 16683403 8896423 12516408
46	STAT5B	Signal Transducer And Activator Of Transcription 5B	Protein Coding	12.23	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	12411494
47	HCK	HCK Proto-Oncogene, Src Family Tyrosine Kinase	Protein Coding	12.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17344919 16546576 9390404
48	MECOM	MDS1 And EVI1 Complex Locus	Protein Coding	11.93	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	7808006
49	DNTT	DNA Nucleotidylexotransferase	Protein Coding	11.9	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	16918360 7924695 1996546 (more) 8366299 9309115 1592097
50	GRB2	Growth Factor Receptor Bound Protein 2	Protein Coding	11.89	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	15143164

Sources

Variations for Leukemia, Chronic Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Chronic Myeloid:

⁷⁵

#	Symbol	AA change	Variation ID	SNP ID
1	SETBP1	p.Asp868Asn	VAR_063807	rs267607042
2	SETBP1	p.Gly870Ser	VAR_063809	rs267607040
3	SETBP1	p.Ile871Thr	VAR_063810	rs267607038
4	SETBP1	p.Glu858Lys	VAR_069849	rs117870202

ClinVar genetic disease variations for Leukemia, Chronic Myeloid:

⁶ (show top 50) (show all 74)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	SETBP1	NM_015559.2(SETBP1): c.2608G> A (p.Gly870Ser)	single nucleotide variant	Pathogenic	rs267607040	GRCh37	Chromosome 18, 42531913: 42531913
2	SETBP1	NM_015559.2(SETBP1): c.2608G> A (p.Gly870Ser)	single nucleotide variant	Pathogenic	rs267607040	GRCh38	Chromosome 18, 44951948: 44951948
3	ABL1	NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913459	GRCh37	Chromosome 9, 133748283: 133748283
4	ABL1	NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913459	GRCh38	Chromosome 9, 130872896: 130872896
5	ABL1	NM_007313.2(ABL1): c.763G> A (p.Glu255Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs387906517	GRCh37	Chromosome 9, 133738306: 133738306
6	ABL1	NM_007313.2(ABL1): c.763G> A (p.Glu255Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs387906517	GRCh38	Chromosome 9, 130862919: 130862919
7	ABL1	NM_007313.2(ABL1): c.814T> C (p.Tyr272His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913461	GRCh37	Chromosome 9, 133738357: 133738357
8	ABL1	NM_007313.2(ABL1): c.814T> C (p.Tyr272His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913461	GRCh38	Chromosome 9, 130862970: 130862970
9	ABL1	NM_007313.2(ABL1): c.1109T> C (p.Met370Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913457	GRCh37	Chromosome 9, 133748391: 133748391
10	ABL1	NM_007313.2(ABL1): c.1109T> C (p.Met370Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913457	GRCh38	Chromosome 9, 130873004: 130873004
11	JAK2	NM_004972.3(JAK2): c.1849G> T (p.Val617Phe)	single nucleotide variant	Pathogenic	rs77375493	GRCh37	Chromosome 9, 5073770: 5073770
12	JAK2	NM_004972.3(JAK2): c.1849G> T (p.Val617Phe)	single nucleotide variant	Pathogenic	rs77375493	GRCh38	Chromosome 9, 5073770: 5073770
13	NRAS	NM_002524.4(NRAS): c.34G> C (p.Gly12Arg)	single nucleotide variant	Pathogenic	rs121913250	GRCh37	Chromosome 1, 115258748: 115258748
14	NRAS	NM_002524.4(NRAS): c.34G> C (p.Gly12Arg)	single nucleotide variant	Pathogenic	rs121913250	GRCh38	Chromosome 1, 114716127: 114716127
15	KIT	NM_000222.2(KIT): c.1621A> C (p.Met541Leu)	single nucleotide variant	Benign/Likely benign	rs3822214	GRCh37	Chromosome 4, 55593464: 55593464
16	KIT	NM_000222.2(KIT): c.1621A> C (p.Met541Leu)	single nucleotide variant	Benign/Likely benign	rs3822214	GRCh38	Chromosome 4, 54727298: 54727298
17	BCR	NM_004327.3(BCR): c.2699A> G (p.Asn900Ser)	single nucleotide variant	not provided	rs752530462	GRCh37	Chromosome 22, 23631800: 23631800
18	BCR	NM_004327.3(BCR): c.2699A> G (p.Asn900Ser)	single nucleotide variant	not provided	rs752530462	GRCh38	Chromosome 22, 23289613: 23289613
19	BCR	NM_004327.3(BCR): c.2707+21G> T	single nucleotide variant	not provided	rs527236142	GRCh37	Chromosome 22, 23631829: 23631829
20	BCR	NM_004327.3(BCR): c.2707+21G> T	single nucleotide variant	not provided	rs527236142	GRCh38	Chromosome 22, 23289642: 23289642
21	BCR	NM_004327.3(BCR): c.2750T> A (p.Val917Asp)	single nucleotide variant	not provided	rs527236143	GRCh37	Chromosome 22, 23632568: 23632568
22	BCR	NM_004327.3(BCR): c.2750T> A (p.Val917Asp)	single nucleotide variant	not provided	rs527236143	GRCh38	Chromosome 22, 23290381: 23290381
23	BRAF	NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser)	single nucleotide variant	Likely pathogenic	rs121913370	GRCh37	Chromosome 7, 140453193: 140453193
24	BRAF	NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser)	single nucleotide variant	Likely pathogenic	rs121913370	GRCh38	Chromosome 7, 140753393: 140753393
25	CSF3R	NM_156039.3(CSF3R): c.1853C> T (p.Thr618Ile)	single nucleotide variant	Pathogenic/Likely pathogenic	rs796065343	GRCh37	Chromosome 1, 36933434: 36933434
26	CSF3R	NM_156039.3(CSF3R): c.1853C> T (p.Thr618Ile)	single nucleotide variant	Pathogenic/Likely pathogenic	rs796065343	GRCh38	Chromosome 1, 36467833: 36467833
27	ABL1	NM_005157.5(ABL1): c.730A> G (p.Met244Val)	single nucleotide variant	Likely pathogenic	rs121913456	GRCh37	Chromosome 9, 133738330: 133738330
28	ABL1	NM_005157.5(ABL1): c.730A> G (p.Met244Val)	single nucleotide variant	Likely pathogenic	rs121913456	GRCh38	Chromosome 9, 130862943: 130862943
29	ABL1	NM_005157.5(ABL1): c.742C> G (p.Leu248Val)	single nucleotide variant	Likely pathogenic	rs121913455	GRCh37	Chromosome 9, 133738342: 133738342
30	ABL1	NM_005157.5(ABL1): c.742C> G (p.Leu248Val)	single nucleotide variant	Likely pathogenic	rs121913455	GRCh38	Chromosome 9, 130862955: 130862955
31	ABL1	NM_005157.5(ABL1): c.749G> A (p.Gly250Glu)	single nucleotide variant	Likely pathogenic	rs121913453	GRCh37	Chromosome 9, 133738349: 133738349
32	ABL1	NM_005157.5(ABL1): c.749G> A (p.Gly250Glu)	single nucleotide variant	Likely pathogenic	rs121913453	GRCh38	Chromosome 9, 130862962: 130862962
33	ABL1	NM_005157.5(ABL1): c.756G> C (p.Gln252His)	single nucleotide variant	Likely pathogenic	rs121913458	GRCh37	Chromosome 9, 133738356: 133738356
34	ABL1	NM_005157.5(ABL1): c.756G> C (p.Gln252His)	single nucleotide variant	Likely pathogenic	rs121913458	GRCh38	Chromosome 9, 130862969: 130862969
35	ABL1	NM_007313.2(ABL1): c.813G> T (p.Gln271His)	single nucleotide variant	Likely pathogenic	rs121913458	GRCh37	Chromosome 9, 133738356: 133738356
36	ABL1	NM_007313.2(ABL1): c.813G> T (p.Gln271His)	single nucleotide variant	Likely pathogenic	rs121913458	GRCh38	Chromosome 9, 130862969: 130862969
37	ABL1	NM_005157.5(ABL1): c.758A> T (p.Tyr253Phe)	single nucleotide variant	Likely pathogenic	rs121913460	GRCh37	Chromosome 9, 133738358: 133738358
38	ABL1	NM_005157.5(ABL1): c.758A> T (p.Tyr253Phe)	single nucleotide variant	Likely pathogenic	rs121913460	GRCh38	Chromosome 9, 130862971: 130862971
39	ABL1	NM_007313.2(ABL1): c.820G> A (p.Glu274Lys)	single nucleotide variant	Likely pathogenic	rs121913448	GRCh37	Chromosome 9, 133738363: 133738363
40	ABL1	NM_007313.2(ABL1): c.820G> A (p.Glu274Lys)	single nucleotide variant	Likely pathogenic	rs121913448	GRCh38	Chromosome 9, 130862976: 130862976
41	ABL1	NM_005157.5(ABL1): c.764A> T (p.Glu255Val)	single nucleotide variant	Likely pathogenic	rs121913449	GRCh37	Chromosome 9, 133738364: 133738364
42	ABL1	NM_005157.5(ABL1): c.764A> T (p.Glu255Val)	single nucleotide variant	Likely pathogenic	rs121913449	GRCh38	Chromosome 9, 130862977: 130862977
43	ABL1	NM_005157.5(ABL1): c.847T> G (p.Phe283Val)	single nucleotide variant	Likely pathogenic	rs1057519758	GRCh37	Chromosome 9, 133747540: 133747540
44	ABL1	NM_005157.5(ABL1): c.847T> G (p.Phe283Val)	single nucleotide variant	Likely pathogenic	rs1057519758	GRCh38	Chromosome 9, 130872153: 130872153
45	ABL1	NM_005157.5(ABL1): c.951C> A (p.Phe317Leu)	single nucleotide variant	Likely pathogenic	rs121913451	GRCh37	Chromosome 9, 133748290: 133748290
46	ABL1	NM_005157.5(ABL1): c.951C> A (p.Phe317Leu)	single nucleotide variant	Likely pathogenic	rs121913451	GRCh38	Chromosome 9, 130872903: 130872903
47	ABL1	NM_007313.2(ABL1): c.1008C> G (p.Phe336Leu)	single nucleotide variant	Likely pathogenic	rs121913451	GRCh37	Chromosome 9, 133748290: 133748290
48	ABL1	NM_007313.2(ABL1): c.1008C> G (p.Phe336Leu)	single nucleotide variant	Likely pathogenic	rs121913451	GRCh38	Chromosome 9, 130872903: 130872903
49	ABL1	NM_005157.5(ABL1): c.1064A> G (p.Glu355Gly)	single nucleotide variant	Likely pathogenic	rs121913450	GRCh37	Chromosome 9, 133748403: 133748403
50	ABL1	NM_005157.5(ABL1): c.1064A> G (p.Glu355Gly)	single nucleotide variant	Likely pathogenic	rs121913450	GRCh38	Chromosome 9, 130873016: 130873016

Copy number variations for Leukemia, Chronic Myeloid from CNVD:

⁷ (show all 45)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	37133	1	858000	52858291	Copy numbercopy numb erLOH		Chronic myeloid leukemia
2	44672	10	61218526	61336824	Translate	D10S170	Chronic myelogenous leukemia
3	56890	11	61840484	62345935	Loss		Chronic myeloid leukemia
4	59436	11	75208816	75845444	Loss		Chronic myeloid leukemia
5	78023	13	48911492	50087172	Loss		Chronic myeloid leukemia
6	83260	14	19767470	106339477	Gain		Chronic myeloid leukemia
7	84230	14	24600000	33300000	Deletion		Chronic myeloid leukemia
8	99762	16	28519207	31440323	Loss		Chronic myeloid leukemia
9	138867	2	172217486	173146666	Loss		Chronic myeloid leukemia
10	143230	2	234301355	238853232	Loss		Chronic myeloid leukemia
11	162523	22	21962191	22180167	Loss		Chronic myeloid leukemia
12	162524	22	21962191	22410163	Loss		Chronic myeloid leukemia
13	162525	22	21962191	23748456	Loss		Chronic myeloid leukemia
14	162526	22	21963005	23840758	Loss		Chronic myeloid leukemia
15	162527	22	21965685	22103948	Loss		Chronic myeloid leukemia
16	162528	22	21965685	22211587	Loss		Chronic myeloid leukemia
17	162529	22	21965685	22575018	Loss		Chronic myeloid leukemia
18	162530	22	21965685	23038955	Loss		Chronic myeloid leukemia
19	162531	22	21965685	23404027	Loss		Chronic myeloid leukemia
20	162532	22	21965685	23779268	Loss		Chronic myeloid leukemia
21	162533	22	21969649	23264408	Loss		Chronic myeloid leukemia
22	162539	22	21996232	23317147	Loss		Chronic myeloid leukemia
23	162540	22	22020300	22659711	Loss		Chronic myeloid leukemia
24	162567	22	22184646	22476629	Loss		Chronic myeloid leukemia
25	162599	22	22374488	22513875	Loss		Chronic myeloid leukemia
26	162992	22	23595985	23627388	Copy number		Chronic myeloid leukemia
27	227187	7	65425674	65447246	Copy number	GUSB	Chronic myeloid leukemia
28	229935	7	97199324	142723486	Loss		Chronic myeloid leukemia
29	231976	8	109706119	120929916	Loss		Chronic myeloid leukemia
30	239048	8	3687491	5908007	Loss		Chronic myeloid leukemia
31	247260	9	129645960	132672275	Loss		Chronic myeloid leukemia
32	247319	9	130014643	132618574	Loss		Chronic myeloid leukemia
33	247584	9	130432414	131425779	Loss		Chronic myeloid leukemia
34	247725	9	130855419	132584828	Loss		Chronic myeloid leukemia
35	247730	9	130896183	132618574	Loss		Chronic myeloid leukemia
36	247834	9	131532978	132607062	Loss		Chronic myeloid leukemia
37	247856	9	131641050	132590178	Loss		Chronic myeloid leukemia
38	247886	9	131997035	132590178	Loss		Chronic myeloid leukemia
39	247924	9	132362204	132593161	Loss		Chronic myeloid leukemia
40	247932	9	132430323	132610819	Loss		Chronic myeloid leukemia
41	248025	9	132985174	134219212	Loss		Chronic myeloid leukemia
42	248051	9	133107127	133390056	Loss		Chronic myeloid leukemia
43	248180	9	133589267	133763060	Copy number	ABL1	Chronic myeloid leukemia
44	250432	9	212399	32604310	Loss		Chronic myeloid leukemia
45	251914	9	3330	20811568	Copy numbercopy numb erLOH		Chronic myeloid leukemia

Sources

Expression for Leukemia, Chronic Myeloid

Search GEO for disease gene expression data for Leukemia, Chronic Myeloid.

Sources

Pathways for Leukemia, Chronic Myeloid

Pathways related to Leukemia, Chronic Myeloid according to KEGG:

³⁷

#	Name	Kegg Source Accession
1	Chronic myeloid leukemia	hsa05220

Pathways related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.63	ABL1 BCR CRKL NRAS PDGFRA RUNX1
2	Pathways in cancer ³⁷	12.28	ABL1 BCR CRKL CSF3R JAK2 NRAS
3	JAK-STAT signaling pathway (KEGG) ³⁷ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵	12.13	ABL1 CSF3R JAK2 NRAS PDGFRA
4	Tyrosine Kinases / Adaptors ⁴	11.72	ABL1 BCR CRKL JAK2 PDGFRA
5	MicroRNAs in cancer ³⁷	11.7	ABL1 CRKL MIR10A MIR203A MIR20A MIR223
6	Jak-Stat Signaling Pathway (sino) ⁶⁷	11.57	ABL1 CSF3R JAK2 NRAS
7	Imatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶¹ Show member pathways Clozapine Pathway, Pharmacokinetics ⁶¹ Doxepin Pathway, Pharmacokinetics ⁶¹ Fluoxetine Pathway, Pharmacokinetics ⁶¹ Gefitinib Pathway, Pharmacokinetics ⁶¹ Nevirapine Pathway, Pharmacokinetics ⁶¹ Pazopanib Pathway, Pharmacokinetics ⁶¹ Warfarin Pathway, Pharmacokinetics ⁶¹	11.5	ABL1 BCR PDGFRA
8	Transcription_Transcription factor Tubby signaling pathways ²²	11.05	ABL1 JAK2 NRAS
9	LncRNA-mediated mechanisms of therapeutic resistance ¹	10.51	HOTAIR MEG3 UCA1

Sources

GO Terms for Leukemia, Chronic Myeloid

Cellular components related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	micro-ribonucleoprotein complex	GO:0035068	9.1	H19 MEG3 MIR10A MIR203A MIR20A MIR223

Biological processes related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	peptidyl-tyrosine phosphorylation	GO:0018108	9.62	ABL1 BCR JAK2 PDGFRA
2	protein autophosphorylation	GO:0046777	9.56	ABL1 BCR JAK2 PDGFRA
3	cellular response to lipopolysaccharide	GO:0071222	9.46	ABL1 BCR IRF8 MIR20A
4	regulation of actin cytoskeleton reorganization	GO:2000249	9.43	ABL1 PDGFRA
5	gene silencing by miRNA	GO:0035195	9.43	H19 MEG3 MIR10A MIR203A MIR20A MIR223
6	negative regulation of cell-cell adhesion	GO:0022408	9.4	ABL1 JAK2
7	regulation of myeloid cell differentiation	GO:0045637	9.37	CSF3R RUNX1
8	platelet-derived growth factor receptor signaling pathway	GO:0048008	8.92	ABL1 BCR JAK2 PDGFRA

Molecular functions related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA binding involved in posttranscriptional gene silencing	GO:1903231	9.26	MIR10A MIR203A MIR20A MIR223
2	protein tyrosine kinase activity	GO:0004713	8.92	ABL1 BCR JAK2 PDGFRA

Sources

Sources for Leukemia, Chronic Myeloid

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Leukemia, Chronic Myeloid (CML)

Aliases & Classifications for Leukemia, Chronic Myeloid

MalaCards integrated aliases for Leukemia, Chronic Myeloid:

Characteristics:

Orphanet epidemiological data:

OMIM:

HPO:

Classifications:

External Ids:

Summaries for Leukemia, Chronic Myeloid

Related Diseases for Leukemia, Chronic Myeloid

Diseases in the Myeloid Leukemia family:

Diseases related to Leukemia, Chronic Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Leukemia, Chronic Myeloid via Phenotypic Disease Network (PDN):

Graphical network of the top 20 diseases related to Leukemia, Chronic Myeloid:

Symptoms & Phenotypes for Leukemia, Chronic Myeloid

Symptoms via clinical synopsis from OMIM:

Clinical features from OMIM:

Human phenotypes related to Leukemia, Chronic Myeloid:

UMLS symptoms related to Leukemia, Chronic Myeloid:

MGI Mouse Phenotypes related to Leukemia, Chronic Myeloid:

Drugs & Therapeutics for Leukemia, Chronic Myeloid

FDA approved drugs:

Drugs for Leukemia, Chronic Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cell-based therapeutics:

Cochrane evidence based reviews: leukemia, myelogenous, chronic, bcr-abl positive

Genetic Tests for Leukemia, Chronic Myeloid

Genetic tests related to Leukemia, Chronic Myeloid:

Anatomical Context for Leukemia, Chronic Myeloid

MalaCards organs/tissues related to Leukemia, Chronic Myeloid:

Publications for Leukemia, Chronic Myeloid

Articles related to Leukemia, Chronic Myeloid:

Genes for Leukemia, Chronic Myeloid

Genes related to Leukemia, Chronic Myeloid (10 elite genes):

Variations for Leukemia, Chronic Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Chronic Myeloid:

ClinVar genetic disease variations for Leukemia, Chronic Myeloid:

Copy number variations for Leukemia, Chronic Myeloid from CNVD:

Expression for Leukemia, Chronic Myeloid

Pathways for Leukemia, Chronic Myeloid

Pathways related to Leukemia, Chronic Myeloid according to KEGG:

Pathways related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

GO Terms for Leukemia, Chronic Myeloid

Cellular components related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

Biological processes related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

Molecular functions related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

Sources for Leukemia, Chronic Myeloid

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :